|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27:v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu T and Dai Y: Tumor microenvironment and
therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ni J, Wu Y, Qi F, Li X, Yu S, Liu S, Feng
J and Zheng Y: Screening the cancer genome atlas database for genes
of prognostic value in acute myeloid Leukemia. Front Oncol.
9:15092019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo J, Xie Y, Zheng Y, Wang C, Qi F, Hu J
and Xu Y: Comprehensive insights on pivotal prognostic signature
involved in clear cell renal cell carcinoma microenvironment using
the ESTIMATE algorithm. Cancer Med. 9:4310–4323. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ni J, Liu S, Qi F, Li X, Yu S, Feng J and
Zheng Y: Screening TCGA database for prognostic genes in lower
grade glioma microenvironment. Ann Transl Med. 8:2092020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen H and Boutros PC: VennDiagram: A
package for the generation of highly-customizable Venn and Euler
diagrams in R. BMC Bioinformatics. 12:352011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chatterjee S, Behnam Azad B and Nimmagadda
S: The intricate role of CXCR4 in cancer. Adv Cancer Res.
124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu C, Zhao H, Chen H and Yao Q: CXCR4 in
breast cancer: Oncogenic role and therapeutic targeting. Drug Des
Devel Ther. 9:4953–4964. 2015.PubMed/NCBI
|
|
16
|
Xu C, Zheng L, Li D, Chen G, Gu J, Chen J
and Yao Q: CXCR4 overexpression is correlated with poor prognosis
in colorectal cancer. Life Sci. 208:333–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding Y and Du Y: Clinicopathological
significance and prognostic role of chemokine receptor CXCR4
expression in pancreatic ductal adenocarcinoma, a meta-analysis and
literature review. Int J Surg. 65:32–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Q, Sun Y and Liu X: CXCR4 as a
prognostic biomarker in gastrointestinal cancer: A meta-analysis.
Biomarkers. 24:510–516. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei
ZW, Zhu JT, Yu J, Chen W, He Y, Schwarz RE, et al: A positive
crosstalk between CXCR4 and CXCR2 promotes gastric cancer
metastasis. Oncogene. 36:5122–5133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Romanuik TL, Wang G, Morozova O, Delaney
A, Marra MA and Sadar MD: LNCaP Atlas: Gene expression associated
with in vivo progression to castration-recurrent prostate cancer.
BMC Med Genomics. 3:432010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akiyama K, Ohga N, Maishi N, Hida Y,
Kitayama K, Kawamoto T, Osawa T, Suzuki Y, Shinohara N, Nonomura K,
et al: The F-prostaglandin receptor is a novel marker for tumor
endothelial cells in renal cell carcinoma. Pathol Int. 63:37–44.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cebola I, Custodio J, Muñoz M,
Díez-Villanueva A, Paré L, Prieto P, Aussó S, Coll-Mulet L, Boscá
L, Moreno V and Peinado MA: Epigenetics override pro-inflammatory
PTGS transcriptomic signature towards selective hyperactivation of
PGE2 in colorectal cancer. Clin Epigenetics. 7:742015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Z, Chan EC and Druey KM: R4 regulator
of G protein signaling (RGS) proteins in inflammation and immunity.
AAPS J. 18:294–304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moratz C, Kang VH, Druey KM, Shi CS,
Scheschonka A, Murphy PM, Kozasa T and Kehrl JH: Regulator of G
protein signaling 1 (RGS1) markedly impairs Gi alpha signaling
responses of B lymphocytes. J Immunol. 164:1829–1838. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moratz C, Hayman JR, Gu H and Kehrl JH:
Abnormal B-cell responses to chemokines, disturbed plasma cell
localization, and distorted immune tissue architecture in
Rgs1-/-mice. Mol Cell Biol. 24:5767–5775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Agenes F, Bosco N, Mascarell L, Fritah S
and Ceredig R: Differential expression of regulator of G-protein
signalling transcripts and in vivo migration of CD4+ naive and
regulatory T cells. Immunology. 115:179–188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kveberg L, Ryan JC, Rolstad B and
Inngjerdingen M: Expression of regulator of G protein signalling
proteins in natural killer cells, and their modulation by Ly49A and
Ly49D. Immunology. 115:358–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi GX, Harrison K, Han SB, Moratz C and
Kehrl JH: Toll-like receptor signaling alters the expression of
regulator of G protein signaling proteins in dendritic cells:
Implications for G protein-coupled receptor signaling. J Immunol.
172:5175–5184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu CJ, Liu TY, Kuo LT, Cheng HW, Chu TH,
Chang KW and Lin SC: Differential gene expression signature between
primary and metastatic head and neck squamous cell carcinoma. J
Pathol. 214:489–497. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huen NY, Pang AL, Tucker JA, Lee TL,
Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM,
et al: Up-regulation of proliferative and migratory genes in
regulatory T cells from patients with metastatic
castration-resistant prostate cancer. Int J Cancer. 133:373–382.
2013. View Article : Google Scholar : PubMed/NCBI
|
